Mercury Laboratories Limited Share Price
Mercury Laboratories Limited Returns Calculator
About Mercury Laboratories Limited
Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. It is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, and innovative products. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.
Mercury Laboratories Limited Financial Highlights
- Revenue: Mercury Laboratories Limited reported revenue of ā¹77.90 crore in FY26 vs ā¹76.17 crore in FY25. It showed an increase of 2.27% on a yearly basis.
- Operating Profit: Mercury Laboratories Limited reported an operating profit of ā¹6.64 crore in FY26 vs ā¹4.66 crore in FY25. It showed an increase of 42.49% on a year-on-year basis.
- Net Profit: Mercury Laboratories Limited reported a net profit of ā¹4.83 crore in FY26 vs ā¹3.14 crore in FY25. It showed an increase of 53.82% on a yearly basis.
Mercury Laboratories Limited Quarterly Result Highlights
- Mercury Laboratories Limited reported revenue of ā¹16.01 crore in Jun 2026, compared with ā¹21.11 crore in Mar 2026, representing a decrease of 24.16% on a quarter-on-quarter (QoQ) basis.
- Mercury Laboratories Limited reported an operating profit of ā¹0.39 crore in Jun 2026, compared with ā¹1.74 crore in Mar 2026, representing a decrease of 77.59% on a quarter-on-quarter (QoQ) basis.
- Mercury Laboratories Limited reported a profit of ā¹0.30 crore in Jun 2026, compared with ā¹1.23 crore in Mar 2026, reflecting a decrease of 75.61% on a QoQ basis.
- The earnings per share (EPS) of Mercury Laboratories Limited stood at ā¹26.21 during Jun 2026.
| Sep 2025 | 0.00% |
|---|---|
| Dec 2025 | 0.00% |
| Mar 2026 | 0.00% |
| Jun 2026 | 0.00% |
Mercury Laboratories Limited Shareholder Returns
Mercury Laboratories Limited Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,63,180.00 | 38.28 | 5.55 | 13.74% | 0.61 | 17.33% | 93.24 | 0.83% | 0.48 | 10.90 |
| Divis Laboratories | 2,43,302.00 | 83.79 | 14.62 | 15.32% | 0.00 | 19.56% | 629.49 | 0.32% | 0.55 | 98.19 |
| Torrent Pharmaceuticals | 1,88,623.00 | 88.29 | 22.64 | 25.49% | 1.69 | 13.85% | 222.76 | 0.68% | 0.49 | 58.70 |
| Zydus Lifesciences | 1,16,114.00 | 25.00 | 4.24 | 18.59% | 0.31 | 17.35% | 237.30 | 0.09% | 0.33 | 35.38 |
| Cipla | 1,14,554.00 | 34.02 | 3.32 | 11.27% | 0.00 | 14.95% | 423.36 | 0.92% | 0.45 | 43.52 |
| Laurus Labs | 1,00,660.00 | 92.32 | 18.99 | 16.77% | 0.40 | 16.14% | 97.20 | 0.11% | 0.67 | 13.72 |
| Lupin | 98,312.20 | 17.73 | 4.38 | 23.76% | 0.04 | 24.88% | 659.00 | 0.84% | 0.57 | 129.18 |
| Dr. Reddy's Laboratories | 96,906.30 | 30.44 | 2.55 | 11.07% | 0.18 | 12.54% | 377.95 | 0.69% | 0.41 | 38.68 |
| Mankind Pharma | 97,467.00 | 47.54 | 6.03 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.44 | 49.37 |
| Aurobindo Pharma | 96,836.10 | 25.68 | 2.52 | 9.25% | 0.19 | 11.76% | 394.82 | 0.24% | 0.38 | 41.58 |
Mercury Laboratories Limited Financials
Income Statement Ā· Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ā¹75.10 | ā¹75.56 | ā¹75.33 | ā¹57.92 |
| Other Income | ā¹1.07 | ā¹1.09 | ā¹1.72 | ā¹0.82 |
| Total Revenue | ā¹76.17 | ā¹76.65 | ā¹77.05 | ā¹58.74 |
| Total Expenses | ā¹71.51 | ā¹69.73 | ā¹69.61 | ā¹53.83 |
| Profit Before Tax | ā¹4.66 | ā¹6.92 | ā¹7.44 | ā¹5.03 |
| Tax | ā¹1.52 | ā¹1.27 | ā¹1.87 | ā¹1.47 |
| Profit After Tax | ā¹3.14 | ā¹5.65 | ā¹5.58 | ā¹3.56 |
| EPS - Basic | ā¹26.21 | ā¹47.12 | ā¹46.49 | ā¹29.68 |
| EPS - Diluted | ā¹26.21 | ā¹47.12 | ā¹46.49 | ā¹29.68 |
Cash Flow Ā· Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ā¹4.66 | ā¹6.92 | ā¹7.44 | ā¹5.03 |
| Income before WC changes | ā¹8.14 | ā¹10.12 | ā¹10.29 | ā¹7.91 |
| Change in Assets | -ā¹5.77 | ā¹0.40 | -ā¹6.11 | ā¹3.85 |
| Change in Liabilities | ā¹4.03 | -ā¹1.04 | -ā¹0.63 | -ā¹4.66 |
| Change in WC | -ā¹1.75 | -ā¹0.64 | -ā¹6.73 | -ā¹0.80 |
| Cash flow from Operations | ā¹4.00 | ā¹8.23 | ā¹2.45 | ā¹5.19 |
| Cash flow from Investing | -ā¹9.04 | -ā¹6.27 | -ā¹1.06 | -ā¹1.89 |
| Cash flow from Financing | -ā¹0.99 | -ā¹1.04 | -ā¹1.01 | -ā¹1.23 |
| Total Cash Flow | -ā¹6.03 | ā¹0.91 | ā¹0.38 | ā¹2.07 |
| Cash (Start of the year) | ā¹8.23 | ā¹7.32 | ā¹6.93 | ā¹4.87 |
| Cash (End of the year) | ā¹2.19 | ā¹8.23 | ā¹7.32 | ā¹6.93 |
Balance Sheet Ā· Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ā¹34.16 | ā¹28.12 | ā¹24.71 | ā¹27.21 |
| Current Assets | ā¹40.08 | ā¹39.84 | ā¹39.46 | ā¹35.22 |
| Total Assets | ā¹74.24 | ā¹67.96 | ā¹64.16 | ā¹62.43 |
| Current Liabilities | ā¹15.08 | ā¹12.63 | ā¹14.18 | ā¹15.75 |
| Net Current Asset | ā¹25.00 | ā¹27.20 | ā¹25.28 | ā¹19.47 |
| Non-Current Liabilities | ā¹5.59 | ā¹4.49 | ā¹4.36 | ā¹6.38 |
| Equity Capital | ā¹53.57 | ā¹50.84 | ā¹45.63 | ā¹40.31 |
| Total Equity & Liabilities | ā¹74.24 | ā¹67.96 | ā¹64.16 | ā¹62.43 |
Popular Stocks
Mercury Laboratories Limited Share Price FAQs
What is Mercury Laboratories Limited share price today?
Mercury Laboratories Limited share price is ā¹753.20 as on 02 Sep, 2026, 14:59 IST.
How has the Mercury Laboratories Limited share price performed in the past?
In the last 1 year, Mercury Laboratories Limited delivered a return of -10.30%. The Mercury Laboratories Limited share price hit a high of ā¹942.90 and low of ā¹620.55.
How much is the Mutual Fund shareholding in Mercury Laboratories Limited shares?
The Mutual Fund Shareholding in Mercury Laboratories Limited was 0.00% at the end of Jun 2026.
What is the the 52-week high and low of Mercury Laboratories Limited shares ?
The 52-week high and low of Mercury Laboratories Limited share is ā¹942.90 and ā¹620.55 as of 02 Sep, 2026.
What is the market cap of Mercury Laboratories Limited?
The market capitalisation of Mercury Laboratories Limited is ā¹90.38 Crores as on 02 Sep, 2026.
What are the stock symbols of Mercury Laboratories Limited?
The stock symbol of Mercury Laboratories Limited is 538964 on the BSE, and the ISIN is INE947G01011.
What was yesterday's closing price for Mercury Laboratories Limited shares ?
Mercury Laboratories Limited shares closed yesterday at ā¹753.20 on BSE
How to buy Mercury Laboratories Limited shares?
To buy Mercury Laboratories Limited shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Mercury Laboratories Limited shares on Holidays?
No, shares of Mercury Laboratories Limited or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Mercury Laboratories Limited shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Mercury Laboratories Limited?
The PE and PB ratio of Mercury Laboratories Limited is 21.71 and 1.56 respectively, as on 02 Sep, 2026, 14:59 IST.
